Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Public Offering Nets $17.5M

NEW YORK (GenomeWeb News) – Vermillion today announced the closing of a public offering of stock that raised $17.5 million in net proceeds.

The company offered 9,602,500 shares of common stock at $1.96 per share, including 1,252,500 shares sold pursuant to the underwriters' option to purchase additional shares.

Canaccord Genuity acted as sole book-running manager, and Roth Capital Partners was lead manager for the offering.

The company said it plans to use the proceeds to fund domestic and international commercialization efforts, enhancements to its bioinformatics platform, and an expansion of its portfolio.

Vermillion stock was up 3 percent at $2.05 in early Friday afternoon trading on the Nasdaq.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.